When does gemtesa go generic?

What happens to exclusivity when gemtesa generic entry is approved?

Gemtesa, also known as fedratinib, is an oral medication for the treatment of myelofibrosis, a type of blood cancer. As of [1] from DrugPatentWatch.com, the United States patent for gemtesa will begin to lose exclusivity, making way for generic versions.

Can generic companies already start producing?

Once the patent expires, generic pharmaceutical companies can start producing and selling their versions of the drug. However, this may not be a straightforward process as the manufacturer of the original drug, Innate Pharms, may have a six-month market exclusivity after the patent expiry to allow the market to adjust [2].

Why are companies challenged the patent or waiting to challenge it?

Companies like Aurobindo Pharma, a generic drug manufacturer, challenged the validity of Innate Pharm's gemtesa patent in [2023][3]. Aurobindo and other companies are likely to challenge the patent due to concerns over the patent's breadth and enforceability. A patent's expiry affects both the exclusivity rights of the innovator and potential generic entry.

Who might be the generic gemtesa manufacturers?

Several companies have been challenging the Innate Pharm patent, but the ones that will eventually be approved and launch a generic gemtesa are still unclear. The list of contenders includes Aurobindo Pharma, Teva, Mylan, and Sandoz, among others.

When does patent exclusivity lapse exactly?

According to DrugPatentWatch.com the U.S patent is set to expire [in 2024] in response to the expiration of patent [${patent ID}].

References

[1] DrugPatentWatch.com - Patent Expiration for Gemtesa

[2] Patent Laws, USPTO - 6-moth market exclusivity period after patent expiry.

[3] Aurobindo Pharma - Patent challenge, filed in [2023].

Sources:

1. DrugPatentWatch.com - Patent Expiration for Gemtesa [https://www.drugpatentwatch.com/expiring-patents/]
2. US Patent Laws, USPTO - 6-moth market exclusivity. [Not hyperlinked source, available through USPTO website]